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Abstract.  CD44 is a polymorphic glycoprotein ex- 
pressed on the surface of many tissues and cell lines 
which has been implicated in a number of cellular 
functions including lymphocyte homing to mucosal 
lymphoid tissue (Peyers patches), leukocyte activation, 
lymphopoiesis, and tumor metastasis.  The predomi- 
nant isoform found on human leukocytes, CIM4H, is 
a receptor for hyaluronic acid.  Because of the promi- 
nent role CD44 plays in diverse biological processes, 
we set out to identify the hyaluronic acid binding 
site(s) in the extracellular domain of CD44H.  Using 
truncation and site-directed mutagenesis we identified 
two regions containing  clusters of conserved basic 
residues which are important in hyaluronic acid bind- 
ing.  One of these regions is situated near the NH~ ter- 
minus and is homologous to other hyaluronic acid 
binding proteins including cartilage link protein.  The 
other more membrane proximal region lies outside the 
link protein homologous domain.  Mutagenesis of basic 
residues within these regions established their role as 
determinants  in hyaluronic acid binding.  Mutation of 
Arg 41, a position where a basic residue is conserved 
in all hyaluronic acid binding proteins,  completely 
abolished binding suggesting that this residue plays a 
critical role in hyaluronic acid binding. 
C 
D44 is a broadly distributed polymorphic transmem- 
brahe  glycoprotein  that  is  also  known  as  Pgp-I 
(Hughes et al., 1981; Lesley and Trowbridge,  1982), 
In (Lu)-related p80 (Telen et al.,  1984),  Hermes antigen 
(Jalkanen  et  al.,  1986),  ECMRI/I  (Carter  and  Wayner, 
1988), HU'I~H-1 (GaUatin et al., 1989) and p85 (Quacken- 
bush  et al.,  1990).  Studies  using  mAbs have  implicated 
CD44 in a number of important cellular functions including 
lymphocyte homing  to  mucosal  lymphoid  tissue  (Peyers 
patches;  Jalkanen  et al.,  1987), leukocyte activation  (Huet 
et al.,  1989;  Shimizu  et al.,  1989;  Denning  et al.,  1990; 
Webb et al.,  1990), lymphopoiesis (Miyake et al.,  1990a), 
and as an extracellular  matrix receptor (Carter and Wayner, 
1988; Jalkanen and Jalkanen,  1992). It has become increas- 
ingly apparent that this diverse range of biological functions 
can be attributed to CD44 acting as a cell adhesion molecule. 
Recent reports also suggest that CD44 plays an important 
role in tumor metastasis (Sy et al.,  1991; Gfinthert et al., 
1991), with expression of CD44 transcripts  being elevated in 
many  human  tumors  (Stamenkovic  et al.,  1991) and  re- 
pressed in others (Shtivelman  and Bishop,  1991). 
Isolation and sequencing of cDNAs encoding the predomi- 
nant form of human CD44 expressed by cells of hemopoietic 
originpredicted a 37-kD protein with an NH2-terminal do- 
main  homologous  to  the  cartilage  link  protein  family 
(Stamenkovic  et al.,  1989; Goldstein et al.,  1989).  Subse- 
quent sequencing  of cDNAs encoding  mouse (Zhou et al., 
1989;  Nottenburgh et al.,  1989),  baboon (Idzerda  et al., 
1989),  and bovine (Bosworth  et al.,  1991) CD44 have re- 
vealed >90%  identity  for the predicted NH~-terminal  195 
amino acids and considerable sequence disparity for the re- 
mainder of the extracellular  domain (Bosworth et al., 1991). 
The  NH2-terminal  135-amino  acid domain  of CD44  not 
only has m30% sequence homology to regions of cartilage 
link proteins (D~ak et al., 1986; Doege et al., 1986), but has 
since been shown to be homologous to regions of the pro- 
teoglycans  versican  and aggrecan  (LeBaron et al.,  1992), 
and to a recently described tumor necrosis factor-inducible 
protein TSG-6 (Lee et al., 1992). All of these proteins share 
the property of being able to bind the extracellular  matrix 
glycosaminoglycan  hyaluronic  acid  (HA). t In the case of 
cartilage link protein, the sites for interaction  with HA have 
been determined (Goetinck et al.,  1987). Using mAbs and 
synthetic  peptides  these  sites  were  located  in  tandemly 
repeated sequences characterized  by clusters of positively 
charged amino acids. These tandem repeats lay within the re- 
gion homologous to the other HA-binding proteins including 
CD44. 
There is considerable diversity in the size of CD44 mole- 
cules expressed on different cell types which has been attrib- 
uted to variations  in the degree of glycosylation and also to 
differential splicing of up to 10 exons in the membrane prox- 
1.  Abbreviations  used in  this  paper:  HA,  hyaluronic acid;  Rg,  receptor 
globulins. 
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Brown et al., 1991; Camp et al.,  1991; Stamenkovic et al., 
1991; Jackson et al., 1992; Screaton et al., 1992). In humans 
the predominant hemopoietic form (CD44H) has an actual 
molecular mass of 80-90 kD and is expressed by cells of  both 
mesodermal and neuroectodermal origin. A  splice variant 
called CD44E is a 150-kD protein found mainly on cells of 
epithelial origin, including carcinomas (Stamenkovic et al., 
1991).  This larger CD44E  isoform, like all CD44  splice 
variants, has an identical NH2-terminal  region to CD44H 
but its cDNA codes for an additional 135-amino acid do- 
main which is inserted after amino acid 220 in the 248 resi- 
due extracellular domain of CD44H  (Stamenkovic et al., 
1991). 
CD44H has been shown to bind HA and other glycosami- 
noglycans (Aruffo et al., 1990; Miyake et al., 1990b;  Culty 
et al., 1990), and to extracellular matrix proteins including 
types I and VI collagen and fibronectin (Carter and Wayner, 
1988; Jalkanen and Jalkanen, 1992). Interestingly, CD44E, 
although containing the NH:-terminal domain homologous 
to cartilage link and other HA-binding proteins, has con- 
siderably reduced affinity and/or avidity for HA (Stamenko- 
vic et al., 1991). This is in contrast to the murine homologue 
of CD44E which, upon transfection into a CD44 negative T 
lymphoma cell line, mediated adhesion to HA-bearing cells 
(He et al., 1992). Many tissues also express CD44H but fail 
to bind HA (Hyman et al., 1991). Requirements for HA rec- 
ognition by CD44 are not well defined although it is known 
that the cytoplasmic domain of CD44 is necessary for bind- 
ing HA from solution and that the rnAb IRAWB 14, can in- 
duce HA binding by some CD44+ cell lines that do not con- 
stitutively bind the ligand (Lesley et al.,  1992). 
Because of the prominent role CD44 plays in a number of 
diverse biological processes including leukocyte adhesion, 
we set out to identify  the HA binding site(s) in the extracellu- 
lar domain of CD44.  Using  truncation and  site-directed 
mutagenesis of soluble forms of CD44 we have identified 
two clusters of basic residues that are associated with HA- 
binding.  Mutagenesis  of  specific  amino  acids  in  these 
regions allowed us to identify  critical residues involved in the 
CD44/HA interaction. 
Materials and Methods 
mAbs 
The following anti CD44 mAbs were used in COS cell transfection im- 
munofluorescence  studies:  A3D8  (Sigma  Immunochemicals, St.  Louis, 
MO); BU52 (Binding Site, Inc., San Diego, CA); IM7 (PharMingen, San 
Diego,  CA),  AIG3 (Oncogene Science,  Uniondale, NY),  and F10.44.2 
(R&D Systems,  Minneapolis, MN). 
Construction of Truncated CD44 Rg 
Expression Plasmids 
Mutant CD44 receptor globulins (Rg) plasmids encoding truncations of the 
membrane proximal extracellular domain were prepared by the PCR using 
a CD44H Rg expression plasmid previously described (Aruffo et al., 1990). 
An oligonucleotide  primer was synthesized encoding a complementary se- 
quence upstream of the MluI restriction site in the CMV promotor region 
of  the ~H3M expression vector (Aruffo and Seed, 1987). This primer (FP3) 
had the following sequence: 
5'-GTA CGG GCC AGA TAT ACG CGT TGA CAT TGA TTA-Y 
Reverse primers containing a BglII restriction site were synthesized  with 
the following sequences: 
F1-B 5'-CGC GAG ATC TGA TGT ACA ATe TTC TTC AGG-Y 
FI-C 5'-CGC GAG ATC TAT GGT AAT TGG TCC ATC AAA-3' 
F2  5'-CGC  GAG ATC TTC ACT GGA GGA GCC GCT GCT-Y 
F3  5'-CGC  GAG ATC TGG ACT GTC TTC GTC TTC GTC-Y 
Each primer encoded complementary sequences of regions in the mem- 
brane proximal  extracellular  domain of CD44H.  PCR products therefore 
encoded the initial 131 amino acids of CD44 (H-B), 145 residues (H-C), 
186 residues (F2),  and 210 residues (F3) (see Fig.  1 A). Amino acids are 
numbered from the beginning of the signal peptide.  PCR conditions con- 
sisted of 30 cycles of 1 min at 94°C,  2 rain at 55°C,  and 3 rain at 72°C, 
using Taq polymerase and reagents recommended by the vendor (Perkin El- 
mer Cetus, Emeryville, CA). 
PCR products were digested with HindllI and Bgll] and ligated to HindIIl- 
BamHI-cut CDM7  vector containing genomic sequence encoding the 
hinge, CH2, and CH3 domains of a human IgG1 (Aruifo et al., 1992). Con- 
structs encoding each of the mutants as well as wild-type CD44H Rg and 
CIM4E Rg (Stamenkovic et al., 1991) were transfected into COS cells and 
the resulting fusion proteins recovered from culture supernatants using pro- 
tein A-Sepharose as previously  described (Aruifo  et al.,  1990).  Purified 
proteins were visualized on 7.5% SDS-PAGE under reducing and nonreduc- 
ing conditions. Protein concentrations were determined using a protein esti- 
mation kit (BioRad Labs, Hercules,  CA). 
Construction of CD44 Rg Site-directed Mutant 
Expression Plasmids 
Nine CIM4 Rg site-directed mutants were prepared by encoding the desired 
mutation in overlapping oligonucleotide primers and generating the mutants 
by PCR (Ho et al., 1989), using the CD44H Rg plasmid construct as a tem- 
plate. Mutants were prepared in two groups. The first group involved muta- 
tions of basic residues in a membrane proximal region. Four of these mu- 
tants were prepared encoding one of the following  mutations:  R150A, 
R154A,  K15KA, and R162A.  A  fifth construct was prepared using PCR 
primers encoding the KI58A and RI62A substitutions while a sixth con- 
struct was made with PCR primers encoding all four amino acid substitu- 
tions. Each PCR primer used for this group of mutants also encoded a silent 
point mutation which introduced a KpnI restriction site so that the con- 
structs could be digested and assessed  for correct frame maintenance. 
A second group of three mutants giving rise to amino acid substitutions 
near the NH2-terminus  of CD44 were also prepared in a similar manner 
and encoded the following mutations: R29A, K38A, and R41A. Each PCR 
primer used for this group of mutants also encoded a silent point mutation 
which introduced a BsaI-II restriction enzyme site used for diagnostic diges- 
tion purposes. 
Primers that were required for PCR reactions but not for introducing mu- 
tations included the forward primer FP3 described above while the ieverse 
primer (ScaB) was synthesized encoding a complementary sequence in the 
5' untranslated region of IgG1 genomic DNA. This primer contained a ScaI 
restriction site and had the following sequence: 
5'-GGG ATG CGT CCA GGC AGG-Y 
PCR conditions consisted  of  6 min at 94°C, 3 min at 72°C, 2 min at 55°C 
followed by 25 cycles of 1 mill at 94°C, 2 min at 55°C and 3 rain at 72°C. 
Pfu polymerase and reaction conditions were used as suggested by the ven- 
dor (Stratagene  Corp., La Jolla, CA).  PeR products were digested  with 
Mini and Seal and ligated  to MluI-ScaI-cut CDM7 vector containing 
genomic sequence encoding the hinge and constant domains of a human 
IgG1 (AruIfo et al. 1992). To confirm that the desired mutations had been 
inserted and to verify the absence of secondary mutations, all CIM4Rg site- 
directed mutants were sequenced  by the dideoxy chain termination/exten- 
sion reaction with Sequenase reagents used according to the manufacturer's 
recommendations (United States  Biochemical  Corp.,  Cleveland,  OH). 
Constructs were transfected into COS cells and the resulting fusion proteins 
recovered  from culture supernatants as previously  described. 
Hyaluronic Acid Binding  Assay 
Binding of purified CD44 Rg's to HA was assessed using an ELISA assay. 
Wells of  polystyrene ELISA plates (Cappel, Durham, NC) were coated with 
50 t~l of a stock 5 mg/ml solution of HA (Sigma Immunochemicals) diluted 
to 5 #g/ml in 50 mM sodium carbonate, pH 9.6, for 16 h at 22°C. Remaining 
binding sites were blocked by the addition of 250 #1 of' 10×  Specimen 
Diluent Concentrate (Genetic  Systems,  Seattle,  WA)  diluted  1:10 with 
ddH20, for 1 h at 22°C. After washing with PBS containing 0.05% Tween- 
20 (PBS-Tw), wells were incubated with 50 #1 of various concentrations of 
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Tw, wells were incubated with 50/~1 of goat anti-human F(ab')2 HRP- 
conjugate (Tago  Inc., Budingame, CA) diluted 1:5,000  in the blocking solu- 
tion used above, for 1 h at 22"C. Wells were then washed with PBS-Tw  and 
incubated with 100 ~1 of EIA Chromogen Reagent (Genetic Systems) for 
15 rain at 22°C. The reaction was stopped by the addition of 100 tzl of 1N 
H2SO4 (Genetic Systems) and the optical density measured on an ELISA 
reader at dual wavelengths 450, 630 nm. 
mAb Binding to COS Cell Transfectants 
Plasmids encoding CD44 Rg's were transfected into COS cells using a 
DEAE-dextran procedure (Aruffo et al., 1990). 24 h after transfeetion, cells 
were trypsinized, seeded onto 15  x  35-mm culture dishes and allowed to 
grow another 24 h. Cells were then washed with PBS, fixed  with 2 % formal- 
dehyde (30 rain) and permeabilized with 0.1% Triton X-100 (30 min). Cells 
were then incubated for 30 min with anti CD44 mAbs (diluted 1:200 to 
1:300 in PBS). After washing with PBS, cells were incubated with the ap- 
propriate anti species IgG-FFl'C-conjugated antibody (Tago  Inc.) at a 1:500 
dilution, for 30 rain. Cells were then washed twice with PBS and examined 
by fluorescence microscopy. 
Results 
Preparation of Soluble CD44 Re, Truncation Mutants 
To define the limits of the extracellular domain of CD44H 
involved in HA binding, soluble chimeric proteins were pre- 
pared  containing different-sized  truncations  of the  mem- 
brane  proximal  and  NH2-terminal  domains  of  CD44H 
fused to the hinge, CH2 and CH3 regions of a  human IgG1 
antibody. Four membrane proximal truncation mutants were 
prepared (Fig. 1 A). F1-B encoded the initial 131 amino acids 
of CD44 that make up the domain homologous to other HA- 
binding proteins,  and included all conserved cysteine resi- 
dues that may be involved in disulphide bonding. F1-C and 
F2  constructs  (amino terminal  145  and  186  amino acids, 
respectively) encoded successively larger proteins, with F2 
marking the end of the region of CD44 that is highly con- 
served among species. The F3 truncation mutant (amino ter- 
minal 210 amino acids) encoded a  further region of 24 non- 
conserved residues. 
Plasmids  encoding  these  truncation mutant fusion pro- 
Table L  Binding of Anti-CD44  mAbs to 
COS Cells Transfected with Plasmids Encoding 
CD44 Rg Mutants 
mAb 
Mutant  IM7  BU52  A3D8  A1G3  F10.44.2 
F1-B  -  +  +  ND  ND 
F1-C  +  +  +  ND  ND 
F2  +  +  +  ND  ND 
F3  +  +  +  ND  ND 
29 R/A  +  +  +  +  + 
38 K/A  +  +  +  +  + 
41  R/A  +  +  +  +  + 
150 R/A  +  +  +  +  + 
154 R/A  +  +  +  +  + 
158K/A  +  +  +  +  + 
162 R/A  +  +  +  +  + 
Double  +  +  +  +  + 
Quadruple  -  +  +  +  + 
CD44H  +  +  +  +  + 
CD44E  +  +  +  +  + 
MOCK  ..... 
2 d after transfeetion,  cells were fixed, permeabilized,  and labeled  with the an- 
tibodies listed. Double  refers to the construct  encoding  mutations  at amino  acid 
positions 158 and 162. Quadruple refers to the construct encoding mutations 
at amino acid positions 150, 154, 158, and 162. Mock refers to control COS 
cells  transfected  with CDM8 plasmid  only. +, positive  labeling; -, no labeling. 
teins were prepared  and transfected into COS  cells as de- 
scribed in Materials and Methods.  The resulting CD44 Rg 
proteins were purified using protein A-Sepharose columns 
and gave an average yield of 6  mg/L (Fig.  1 B). 
The structural integrity of each CIM4 Rg truncation mu- 
tant fusion protein was examined by assessing their ability 
to bind three anti-CD44 mAbs. All mutants bound the anti- 
bodies  IM7,  A3D8  and BU52  with  the  exception of F1-B 
which failed to bind IM7 (Table I). IM7 partially inhibits a 
B  cell hybridoma from adhering to a  bone marrow-derived 
Figure 1. CD44 Rg truncation 
mutant fusion genes and puri- 
fied proteins. (A) Fusion  genes 
were constructed wi~ mmcafion 
of cDNA coding for the mem- 
brane proximal region of the 
extraceUular domain of CD44H. 
([])  The  NH2-terminal  135- 
amino acid region homologous 
to other HA-binding  proteins; 
(m) the  remainder of the ex- 
tracellular  domain  up to the site 
where  alternatively  spliced 
exons are inserted (amino acid 
200; Stamenkovic et al., 1991). 
Arrow indicates the site where 
NH2-terminal interspecies CD44 sequence homology ends (amino acid 195). H, CH2, and CH3 denote human IgG1 hinge and constant 
region exons, respectively. Introns are represented by connecting lines. The amino acid sequences predicted at the sites of fusion of the 
truncated extracellular domain with IgG1 are shown below each individual diagram. (B) 35S-labeled  fusion proteins purified from trans- 
fected COS cell culture supernatant by adsorption to protein A-Sepharose columns. Electrophoresis was performed in a 7.5 % SDS-poly- 
acrylamide gel under reducing conditions. Relative molecular mass of protein standards are shown on the left. 
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adhesion of lymphocytes to HA-coated culture wells (Mi- 
yake et al.,  1990b). A3D8 recognizes an epitope on CD44 
that modifies the ability of erythrocyte  LFA-3 to interact with 
human T  cell CD2 molecules (Haynes et al.,  1989).  The 
BU52 antibody has no known biological effect. The differen- 
tial effect of these anti-CD44 mAbs in various biological as- 
says suggests that they recognize distinct CD44 epitopes. 
Four NH2-terminal truncation constructs were also pre- 
pared, corresponding to deletions of the initial 55, 103, 131, 
and 165 amino acids of CD44H, respectively. Each of these 
constructs yielded several protein products when purified 
from culture supernatant by adsorption to and elution from 
protein A affinity columns. None of the anti-CD44 antibod- 
ies listed above bound to these truncation mutants. Because 
of this  apparent  lack  of structural  integrity  of the  NH2- 
terminal  deletion mutants,  they were not used  in  further 
binding studies. 
Binding of CD44 Rg Truncation Mutants to 
Hyaluronic Acid 
To study the binding interaction between CD44 Rg mem- 
brane proximal truncation mutants and HA, an ELISA assay 
was  developed in  which  soluble fusion proteins were in- 
cubated with HA immobilized on polystyrene wells. Bound 
CD44 Rg was detected by adding HRP-labeled anti-human 
IgG antibodies which recognized the human IgG portion of 
the fusion protein. Increasing concentrations of CIM4H Rg 
gave a linear increase in the amount of fusion protein bound 
to HA (Fig.  2).  When truncation mutants were incubated 
with immobilized HA, the two constructs having the smaller 
deletions, F2 and F3, showed enhanced binding with respect 
to CD44H. Despite retaining the cartilage link protein ho- 
:  CO44H 
•  CO44E 
.  /// 
o  --  F2 
.  F3 
A  CD7 
o.o,,.  --  -  ~  ,';" 
0  20  40  6:0 
PROTEIN  (p.g/ml) 
Figure 2. Binding of CD44 Rg truncation mutants to HA. Increas- 
ing concentrations of CD44 Rg truncation mutants were incubated 
with HA immobilized on ELISA plates. Bound fusion protein was 
detected using peroxidase-conjugated goat anti-human F(ab')2 an- 
tibody. CD'/Rg was used as a human IgG fusion protein control. 
Data is expressed as the +SD of duplicate wells and is representa- 
tive of at least three experiments. 
mologous domain, the two constructs that had larger dele- 
tions, F1-B and FI-C, exhibited a marked reduction in their 
ability to bind HA. As controls we used a soluble form of 
the splice variant CD44E which had been shown not to bind 
to HA when expressed on the surface of transfected tumor 
cells, and a CD7 Rg chimera. Both controls showed no ap- 
preciable binding to HA. 
Preparation of CD44 Rg Site-directed Mutants 
Hyaluronate binding assays established that the F2 construct 
was the smallest fully functional membrane proximal dele- 
tion mutant. The extracellular fragment of CD44 contained 
in this construct had two clusters of  positively charged amino 
acids.  One  of these clusters was  near the NH2 terminus, 
within the link protein homologous domain (Fig. 3, shaded 
region B). The other cluster was located outside the link pro- 
tein homologous region in a more membrane proximal posi- 
tion (Fig. 3, shaded region A) which had been deleted in the 
F1-B and F1-C constructs. Because glycosaminoglycans are 
known to interact via basic amino acids with their respective 
protein receptors 0ackson et al.,  1991),  and because both 
cluster  s of positively charged residues are conserved among 
species, we prepared site-directed mutants by individually 
substituting basic residues in each cluster with alanine (Fig. 
3). Two additional mutants were prepared from region A in 
which the last two (double), and all four positively charged 
residues were replaced with alanine. 
Site-directed  mutants  of soluble  CIM4  Rg  were  con- 
structed using PCR oligonucleotide primer-directed muta- 
genesis. PCR products encoding the desired mutations were 
genetically fused to IgG heavy chain hinge and constant do- 
mains i  n .the same manner as the soluble CIM4 Rg truncation 
mutants described above. Subcloning, COS cell transfection 
and Rg purification were also performed as described above. 
An average protein yield of '~7 mg/L was obtained for the 
mutant proteins. 
All constructs were sequenced to confirm that the desired 
mutations had been introduced and to ensure that no spuri- 
ous mutations had been introduced by the PCR methodol- 
ogy. A Tyr to Ser substitution at position 109 was found in 
all  of the constructs.  However, independent CIM4 clones 
also revealed a 109 Ser which is conserved in mouse (Zhou 
et al., 1989, Nottenburgh et al., 1989), bovine (Bosworth et 
';  T T 
zl  3o 
.QIDLN~TCRFAGVFNVEKNGRYSIS-  -TIT IVNROGTRYTKKGEYRT  NPED- 
Y  ¥  ¥  Y  ¥  •  T 
A  A  A  A  A  A  A 
Figure 3. Schematic diagram of CD44H extracellular domain and 
the basic amino acid-rich regions where site-directed mutagenesis 
occurred. Basic amino acids mutated to alanine are indicated in the 
membrane proximal domain (g'Ji~), and the NH2-terminal domain 
(V/~). Amino acids are denoted by their single letter code and num- 
bered from the beginning of the signal sequence (SS). Arrows at 
amino acid positions 135, 195, and 220 indicate the end of the NH2- 
terminal domain homologous to other HA-binding  proteins, the end 
of interspecies CD44 sequence homology, and the site where alter- 
natively spliced exons are inserted, respectively. 
The Journal of Cell Biology,  Volume 122, 1993  260 al., 1991), and baboon CD44 (Idzerda et al., 1989), suggest- 
ing that this difference might have been due to a mistake in 
the original sequencing of the CD44H eDNA (Stamenkovic 
et al.,  1989). 
Binding of CD44 mAbs to Transfected COS Cells 
Expressing Site-directed  Mutants 
To examine whether site-directed mutagenesis had affected 
the structural integrity of mutant fusion proteins, the reactiv- 
ity  of  each  protein  with  five  anti-CIM4  antibodies  was 
tested. All the constructs reacted with the anti-CIM4 mAbs 
with the exception of the antibody IM7 which did not bind 
to the construct containing four mutations (quadruple) in the 
membrane proximal region (Table I). This was an indication 
that in this construct the mutations had either altered the epi- 
tope recognized by IM7 and/or the structure of the mutant 
protein had been perturbed.  A1G3  has an epitope distinct 
from A3G8 (Denning et al.,  1990),  while F10.44.2 has no 
reported effect on the biological function of CD44 (Dalchau 
et al.,  1980). 
Binding of CD44 Site-directed  Mutants to 
Hyaluronic Acid 
To assess the ability of CD44 Rg site-directed mutants to 
bind HA we used the same ELISA assay used to study the 
truncation mutants. Results showed that all four membrane 
proximal mutants encoding a single substitution of a basic 
amino acid with alanine had reduced binding to HA (Fig. 4) 
with the mutant R154A having the least ability to bind HA. 
The construct which had two amino acid substitutions (dou- 
ble; K158A/R162A), showed considerably reduced binding 
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Figure 4. Binding of CD44 Rg membrane proximal  site-directed mu- 
tants to HA. Increasing concentrations of CD44 Rg's encoding site 
directed mutations in the membrane proximal region were incubated 
with HA immobilized on ELISA plates. Bound fusion protein was 
detected as for Fig. 2. DOUBLE refers to the fusion construct con- 
taining both the K158A and R162A mutations.  Data is expressed 
as the +SD of duplicate wells and is representative of at least three 
experiments. 
to HA compared with wild-type CD44H Rg. The construct 
with all four amino acid substitutions had an almost identical 
binding  curve to the double mutation construct  (data not 
shown). 
Interestingly, in ELISAs where HA was substituted with 
other  immobilized glycosaminoglycans, it was found that 
CD44H Rg also bound to chondroitin-4-sulfate and very 
weakly to chondroitin-6-sulfatc, but not to dermatan sulfate 
or heparin sulfate (data not shown).  However "~100  times 
more immobilized chondroitin-4-sulfate  (500  /zg/ml) was 
required to achieve similar binding levels of CD44H Rg as 
that seen with HA (5 #g/ml). It should be noted that neither 
HA nor chondroitin-4-sulfate can bind to plastic unless they 
are coupled in some way to protein which is present as a con- 
taminant  in  the  commercial  glycosaminoglycan prepara- 
tions. Therefore the amount of glycosaminoglycan bound to 
the plate may or may not reflect the concentration that was 
initially added.  The double mutation construct also bound 
to a chondroitin-4-sulfate coated surface but to a much lower 
degree than to HA, even with an "~100-fold greater concen- 
tration of chondroitin-4-sulphate  over HA immobilized to 
the plates (data not shown). 
CD44  Rg NH2-terminal site-directed mutants were also 
tested for their ability to bind HA by ELISA. All three mu- 
tants encoding  single amino acid substitutions  showed re- 
duced binding to immobilized HA with the mutation R41A 
causing an almost complete loss of binding (Fig. 5). The mu- 
tant K38A bound HA somewhat less effectively than CD44H 
while the R29A mutant had HA binding capacity intermedi- 
ate to the other two constructs. 
Discussion 
Truncation mutagenesis and site-directed mutagenesis of a 
J  7.  CD44 H  / 
•  2gR/A  / 
:  a----  38WA 
lO 
g  os 
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Figure 5. Binding of CD44 Rg NH2-terminal site-directed mutants 
to HA. Increasing  concentrations of  CIM4 Rg's encoding site-directed 
mutations in the NH2-terminal region were incubated with HA im- 
mobilized on ELISA plates. Bound fusion protein was detected as 
for Fig. 2. CD7 Rg was used as a human IgG fusion protein control. 
Data is expressed as the +SD of duplicate wells and is representa- 
tive of at least three experiments. 
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tion of  two clusters of  basic residues and specific amino acids 
within these clusters as important determinants in CD44/ 
HA binding.  Truncation mutagenesis established that HA 
binding by wild-type CD44 requires more than just the carti- 
lage link protein homologous domain. A cluster of  positively 
charged amino acids situated membrane proximal to this ho- 
mologous domain plays an important role in HA binding. 
Site-directed mutagenesis of basic residues both within this 
cluster and within a cluster in the NH2-terminal link pro- 
tein homologous domain confirmed that arginine and lysine 
residues  within  these  regions  were  intimately  associated 
with  CD44/HA  binding.  It  appears  that  HA  binding  is 
cooperative between the two basic regions in the extracellu- 
lar domain of CD44. Mutation of any individual basic amino 
acid in either cluster affected the protein's ability to bind its 
ligand. The binding data clearly establishes Arg 41 as a criti- 
cal  residue  in this  interaction,  yet the  double membrane 
proximal  mutant  (K158A/RI62A),  can  also  significantly 
affect HA binding even with an intact Arg 41. 
In contrast to the F2 and F3 truncation mutants, the F1-B 
and F1-C constructs had considerably reduced ability to bind 
HA. This was somewhat of a surprise since the cartilage link 
protein homologous region was  still  present in the NH2- 
terminal region of these deletion mutants. These results sug- 
gested that this reduction in binding may have been due to 
deletion of amino acids not previously thought to interact 
with and bind to HA.  Alternatively, because of the large 
number of deleted amino acids, FI-B and F1-C fusion pro- 
teins may have had an altered secondary structure such that 
they were unable to bind to HA. To address this latter possi- 
bility the ability of the truncation mutants to bind to anti- 
CD44 mAbs was examined. All deletion mutants, when ex- 
pressed in COS cells, bound the antibodies IM7, A3D8, and 
BU52 with the exception of F1-B which failed to bind IM7 
(Table I). We can not completely rule out the possibility that 
these deletions had perturbed the CD44 molecule in such a 
way as to diminish HA binding. However our results suggest 
that the native configuration of the epitopes recognized by 
these antibodies and by extension the CD44 protein frag- 
ments, had been retained and that the loss of binding to HA 
by the F1-B and F1-C truncation mutants was most likely due 
to deletion of amino acids involved in the HA interaction. 
The inability of IM7 to bind to F1-B may have been due to 
removal of  part or all of the epitope recognized by this mAb. 
Recent studies had shown that a membrane-bound trun- 
cated mutant of murine CD44H was still capable of binding 
to  soluble  HA  (He et al.,  1992).  This construct had  an 
83-amino acid deletion immediately proximal to the trans- 
membrane domain, the region least conserved among spe- 
cies. The F2 deletion mutant of human CD44 described here 
is similar to the murine truncation mutant and was also able 
to bind HA (Fig.  1 A). Taken together, this report and the 
results of He et al. (1992) suggest that the region immediately 
proximal to the transmembrane region is not involved in HA 
binding. The F2 deletion mutant did not display diminished 
ability to bind HA while the F1-C mutant showed a marked 
reduction in  HA binding.  The region encoded in F2  but 
deleted from F1-C  contained a  cluster  of four positively 
charged amino acids situated within a 13 residue stretch (po- 
sition 154 to 162).  Site-directed mutagenesis of each of the 
four basic residues confirmed the observation that this re- 
gion, and more specifically the basic residues within, played 
an integral role in HA binding.  Each individual mutation 
caused a  reduction in HA binding while a double mutant 
(K158A/R162A) showed a reduction in binding indicative of 
an additive effect of the two single mutants. This region is 
highly conserved among other species but lies outside the 
domain homologous to other HA-binding proteins and there- 
fore identifies a unique domain involved in HA binding. 
The only other cluster of basic residues that is conserved 
in  CD44  lies  close to the  NH2  terminus  and  is  situated 
within a 135-amino acid region that has 30% sequence ho- 
mology to other known HA binding proteins. Three basic 
residues in this cluster, all of which are conserved among 
species, were mutated to alanine. Of these the arginine 41 
substitution had the greatest impact, eliminating HA binding 
almost completely. This result is of some significance to the 
group of proteins that share this sequence homology and are 
known to bind HA. All members of this group, CD44, link 
protein, versican, aggrecan, and TSG-6 protein, have a basic 
amino acid in the same relative position (Lee et al.,  1992). 
This conservation of structure  suggests  a  conservation of 
function leading us to predict that this residue is also of fun- 
damental importance to the other members of the family in 
their ability to bind HA. It is likely that either an arginine 
or lysine in this position can fulfill the same role in HA bind- 
ing as TSG-6 has a  lysine residue while the other family 
members have an arginine. A basic residue at position 38 is 
less well conserved with arginine present in TSG-6 and link 
protein,  and a  lysine in CD44.  Mutation of lysine 38  in 
CD44 did reduce HA binding but only to a level slightly less 
than normal suggesting that this residue was not as critical 
for binding HA. 
Binding of selected mutant CD44 Rg's to tissue sections 
containing an abundance of HA confirmed the results of HA 
binding studies by ELISA. Whereas wild-type CD44H Rg 
bound extensively to HA present in tissue sections, binding 
by the double mutant K158A/R162A was weaker and binding 
by the  R41A  mutant was  completely abolished  (data  not 
shown). Similar binding properties were observed in ELISA 
assays  suggesting  that  these  mutant  proteins  do  not  dis- 
criminate in their ability to bind HA either immobilized to 
plastic or immobilized in tissue sections. 
Recent studies of glycosaminoglycan-protein interactions 
have  revealed  that  binding  occurs  between  negatively 
charged carboxyl and sulfate groups of the glycosaminogly- 
can and domains of clustered positively charged basic amino 
acids of the protein (Jackson et al.,  1991). Indeed chemical 
modification of proteoglycan core protein (Hardingham et 
al.,  1976), or cartilage link protein (Lyon, 1986), have im- 
plicated the basic  amino acids  arginine and lysine in the 
binding of these macromolecules to HA. Further, HA was 
shown to bind cartilage link protein within domains contain- 
ing clusters of basic amino acids (Goetinck et al.,  1987). 
Clusters of basic amino acids are found in the heparin bind- 
ing domains of several proteins including antithrombin III 
and heparin cofactor II, both of which require heparin bind- 
ing to perform their functions as inhibitors of serine pro- 
teases (Jackson et al.,  1991).  The two heparin binding do- 
mains of antithrombin III are somewhat analogous to the two 
domains in CD44 described here and the tandem repeat do- 
mains of cartilage link protein (Goetinck et al.,  1987) that 
are important in HA binding. A portion of the heparin cofac- 
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fate.  We have shown that CD44  can bind to both HA and 
chondroitin-4-sulfate using a common domain although it is 
unclear  whether  both  glycosaminoglycans  use  the  same 
binding site.  Underhill et al. (1983) previously showed that 
the same binding site of CD44 could bind both HA and chon- 
droitin sulfate.  It is clear that the sulfated chondroitin does 
not bind to CD44 with the same afffinity/avidity  as nonsul- 
fated HA and that the position of the sulfate group in chon- 
droitin is also important as chondroitin-6-sulfate binds very 
weakly to CD44. 
He et al. (1992) have recently shown that a number ofmu- 
rine CD44 splice variants  when expressed on T lymphoma 
cells,  were capable of mediating adhesion to cells bearing 
HA. CD44E is a human homologue of one of these murine 
HA-binding variants  and we have confirmed a previous re- 
port  that  CD44E  has  a  very  limited  ability  to  bind  HA 
whether expressed on transfected tumor cells (Stamenkovic 
et al.,  1991), or as a soluble protein (present study). The ex- 
planation for this discrepancy is unclear. Whether the three 
amino acids deleted (one of which is an arginine) immedi- 
ately upstream of the membrane proximal splice site play a 
role in HA binding remains unknown. CD44E is "~60% ho- 
mologous to the mouse and rat isoforms so amino acid differ- 
ences in the alternatively spliced domain may also be respon- 
sible for the observed differences  in HA binding. This will 
be an important issue to resolve as it would appear that there 
is  an  association  between  the  ability  of  tumor  cells  to 
metastasize and the ability of CD44 isoforms expressed on 
tumor cells to bind HA (Sy et al., 1991; Thomas et al., 1992; 
Giinthert et al.,  1991). 
By genetically manipulating the ability of CD44 to bind 
HA we can now study the biological role of a  number of 
splice  variants  and  determine  whether  these  variants  are 
capable of binding to as yet unidentified ligands and thus pro- 
vide a means to explain the many biological functions attrib- 
uted to CD44. The role CD44 plays in leukocyte trafficking 
(Jalkanen et al., 1987; Culty et al., 1990) can also be studied 
using HA-binding mutants to search for possible ligands ex- 
pressed on high endothelial venules that appear to interact 
with CD44 via a functional domain distinct from the HA- 
binding domain. 
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